PB
Therapeutic Areas
Santen Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DE-130 (Eylea biosimilar) | Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 |
| DE-126 (OTX-TIC) | Primary Open-Angle Glaucoma & Ocular Hypertension | Phase 3 |
| DE-127 (OTX-TKI) | Diabetic Retinopathy / Diabetic Macular Edema (DME) | Phase 2 |
| SEI-117 | Allergic Conjunctivitis | Phase 3 |
| DE-128A | Presbyopia | Phase 2 |
| DE-130 (STN-101) | Dry Eye Disease | Phase 2 |
Leadership Team at Santen Pharmaceutical
TS
Takashi Sato
Representative Director, President and CEO
NS
Naveed Shams
Senior VP, Head of R&D and Chief Scientific Officer
HY
Hiroshi Yamaguchi
Senior VP, Head of Japan Region
AM
Atsushi Minagawa
Senior VP, Chief Financial Officer